Unlabelled: There has been recent controversy regarding the optimal protocol for imaging and ablation of post-thyroidectomy patients. Several authors have suggested that a scanning dose of 185-370 MBq (5-10 mCi) (131)I may be capable of producing a stunning effect on thyroid tissue that may interfere with the uptake and efficacy of the subsequent ablation dose of radioiodine. The purpose of this study was to determine whether a 185-MBq (5 mCi) diagnostic dose of (131)I produces a visually apparent stunning effect 72 h before (131)I ablation therapy.
Methods: One hundred twenty-two consecutive post-thyroidectomy patients for differentiated thyroid carcinoma received a 185-MBq (5 mCi) diagnostic dose of (131)I followed by a whole-body diagnostic scan at 72 h. On the same day the diagnostic scan was completed, the patient was admitted to the hospital and received an (131)I ablation therapy dose of 5550 MBq (150 mCi) in most cases. A postablation, whole-body scan was obtained at 72 h and compared with the previous diagnostic scan for any visual evidence of stunning.
Results: No cases of visually apparent thyroid stunning were observed on any of the postablation scans with regard to the number of (131)I foci identified or the relative intensity of (131)I uptake seen.
Conclusion: Diagnostic whole-body scanning can be performed effectively with a 185-MBq (5 mCi) dose of (131)I 72 h before radioiodine ablation without concern for thyroid stunning.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Stress cardiomyopathy following thyroidectomy in a postmenopausal patient: A case report.
Int J Surg Case Rep
May 2024
Department of Anesthesiology and Intensive Care, University Hospital Alexandrovska, Medical University Sofia, Bulgaria; Medical University Sofia, Faculty of Medicine, Bulgaria. Electronic address:
Introduction And Importance: First described in 1990 in Japan, Stress cardiomyopathy (SC) is characterized by transient systolic and diastolic left ventricular (LV) dysfunction with a variety of wall-motion abnormalities. It predominantly affects postmenopausal women and is often preceded by an emotional or physical trigger. SC is an increasingly recognized form of transient LV dysfunction that is often completely reversible.
View Article and Find Full Text PDFIs there a role for diagnostic scans in the management of intermediate-risk thyroid cancer?
Endocr Relat Cancer
August 2022
Division of Endocrinology, Diabetes and Metabolism, University of Lausanne, Lausanne, Switzerland.
Radioiodine (RAI) is selectively recommended for intermediate-risk differentiated thyroid carcinomas (DTC). The information gleaned from pretherapy stimulated thyroglobulin levels (sTg) and diagnostic 131I whole-body scans (DxWBS) to guide therapy remains controversial. The present study aimed at evaluating the impact of preablation sTg and DxWBS in the management of intermediate-risk DTC.
View Article and Find Full Text PDFA multicenter randomized placebo-controlled trial of intravenous thyroxine for heart-eligible brain-dead organ donors.
Trials
November 2021
Mid-America Transplant, St. Louis, MO, USA.
Background: Brain death frequently induces hemodynamic instability and cardiac stunning. Impairments in cardiac performance are major contributors to hearts from otherwise eligible organ donors not being transplanted. Deficiencies in pituitary hormones (including thyroid-stimulating hormone) may contribute to hemodynamic instability, and replacement of thyroid hormone has been proposed as a means of improving stability and increasing hearts available for transplantation.
View Article and Find Full Text PDFRadio-Iodide Treatment: From Molecular Aspects to the Clinical View.
Cancers (Basel)
February 2021
Departamento de Endocrinología y Nutrición, Hospital Universitario de Móstoles, 28935 Madrid, Spain.
Thyroid radio-iodide therapy (RAI) is one of the oldest known and used targeted therapies. In thyroid cancer, it has been used for more than eight decades and is still being used to improve thyroid tumor treatment to eliminate remnants after thyroid surgery, and tumor metastases. Knowledge at the molecular level of the genes/proteins involved in the process has led to improvements in therapy, both from the point of view of when, how much, and how to use the therapy according to tumor type.
View Article and Find Full Text PDFStress cardiomyopathy following thyroidectomy in a premenopausal woman with thyroid cancer: case report and review of the literature.
Gland Surg
December 2020
Department of Critical Care Medicine, The Fourth Hospital of Hebei Medical University, Hebei Key Laboratory of Critical Disease Mechanism and intervention, Shijiazhuang, China.
Stress cardiomyopathy (SC) is a poorly recognized heart disease that was initially regarded as a benign condition. Recently, it has been shown that SC may be associated with severe clinical complications including death and that its prevalence is probably underestimated. The disease is characterized by transient systolic and diastolic left ventricular (LV) dysfunction with a variety of wall-motion abnormalities.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!